Lpwm LLC Buys Shares of 1,195 Johnson & Johnson (NYSE:JNJ)

Posted by on Apr 11th, 2023

Lpwm LLC acquired a new position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 1,195 shares of the company’s stock, valued at approximately $209,000.

Several other institutional investors have also recently added to or reduced their stakes in JNJ. Glassy Mountain Advisors Inc. purchased a new position in Johnson & Johnson during the fourth quarter worth about $35,000. Retirement Financial Solutions LLC acquired a new position in shares of Johnson & Johnson during the 4th quarter valued at about $40,000. TD Capital Management LLC acquired a new stake in shares of Johnson & Johnson in the third quarter worth approximately $48,000. Iron Horse Wealth Management LLC grew its holdings in Johnson & Johnson by 112.8% in the fourth quarter. Iron Horse Wealth Management LLC now owns 300 shares of the company’s stock valued at $53,000 after purchasing an additional 159 shares during the period. Finally, Piershale Financial Group Inc. acquired a new position in Johnson & Johnson during the fourth quarter worth approximately $61,000. Institutional investors and hedge funds own 67.94% of the company’s stock.

Johnson & Johnson Price Performance

NYSE JNJ opened at $164.32 on Tuesday. Johnson & Johnson has a 12 month low of $150.11 and a 12 month high of $186.69. The firm has a market capitalization of $427.94 billion, a PE ratio of 24.38, a P/E/G ratio of 2.85 and a beta of 0.53. The company’s 50 day simple moving average is $157.42 and its 200 day simple moving average is $167.05. The company has a debt-to-equity ratio of 0.35, a current ratio of 0.99 and a quick ratio of 0.77.

Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.22 by $0.13. The company had revenue of $23.71 billion for the quarter, compared to analysts’ expectations of $23.90 billion. Johnson & Johnson had a return on equity of 35.76% and a net margin of 18.90%. The firm’s revenue for the quarter was down 4.4% on a year-over-year basis. During the same period last year, the firm earned $2.13 EPS. As a group, equities research analysts forecast that Johnson & Johnson will post 10.5 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on JNJ. Atlantic Securities boosted their price objective on shares of Johnson & Johnson from $160.00 to $168.00 and gave the company a “neutral” rating in a research note on Wednesday, January 25th. SVB Leerink dropped their price target on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a research note on Friday, January 20th. UBS Group began coverage on Johnson & Johnson in a research note on Tuesday, March 28th. They issued a “neutral” rating and a $164.00 price objective on the stock. StockNews.com assumed coverage on shares of Johnson & Johnson in a research report on Thursday, March 16th. They set a “strong-buy” rating on the stock. Finally, Citigroup upped their target price on Johnson & Johnson from $198.00 to $205.00 and gave the stock a “buy” rating in a research report on Monday, December 12th. Eight equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $173.60.

Insider Buying and Selling at Johnson & Johnson

In related news, insider James D. Swanson sold 1,062 shares of the stock in a transaction that occurred on Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the sale, the insider now directly owns 9,215 shares of the company’s stock, valued at $1,425,191.90. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.20% of the stock is owned by corporate insiders.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.